Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success

Sarepta’s stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints.


www.marketwatch.com
#Sareptas #stock #plummets #disappointing #trial #data #raise #questions #DMD #drugs #success